China vaccine scandal spreads as it recalls defective products which may have been sold overseas
Public anger soared last month after leaked documents revealed concerns about pharmaceutical safety
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Investigators in China have begun recalling defective vaccines produced by one of the country's drug-makers from domestic and overseas markets, health authorities said.
Investigators found Changchun Changsheng Life Sciences Ltd had blended expired fluids in its vaccines and falsified records from as early as April 2014, the National Health Commission said in a statement.
The names of the overseas countries were not given, but the recall indicated the scandal gripping China may have spread to foreign markets.
The commission did not immediately respond to a request for comment.
Regulators ordered a production halt last month, but public anger soared after documents leaked online showed regulators had found inconsistencies in 2017 but failed to take immediate action.
President Xi Jinping and other top officials have reacted swiftly to contain outrage by condemning Changsheng and pledging improved regulation of food and medicine safety, two areas of perennial concern in China that could fuel anti-government sentiment among the growing urban middle class.
Regulators have launched nationwide spot checks on vaccine makers while the central government has set up a panel of experts to review vaccine safety in China's massive £95bn pharmaceutical industry.
Changsheng was China's second-largest rabies vaccine manufacturer before the scandal hit.
Police in northeast China said last week they would seek the arrest of 18 Changsheng executives, including Chairwoman Gao Junfang.
Associated Press
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments